Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.

Blood Adv · 2026 · PMC12952775 · PMID 41269777

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the differences did not reach statistical significance for the comparison of zanubrutinib vs acalabrutinib, a trend favoring improved rwTTNT and rwOS for zanubrutinib was observed.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.